195 related articles for article (PubMed ID: 32117290)
1. Sedimentation Velocity Analytical Ultracentrifugation of Oxidized Recombinant Full-Length Factor VIII.
Zakas PM; Healey JF; Smith IW; Lillicrap D; Lollar P
Front Immunol; 2020; 11():150. PubMed ID: 32117290
[TBL] [Abstract][Full Text] [Related]
2. Identification of aggregates in therapeutic formulations of recombinant full-length factor VIII products by sedimentation velocity analytical ultracentrifugation.
Healey JF; Parker ET; Lollar P
J Thromb Haemost; 2018 Feb; 16(2):303-315. PubMed ID: 29197156
[TBL] [Abstract][Full Text] [Related]
3. Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.
Delignat S; Peyron I; El Ghazaly M; V Kaveri S; Rohde J; Mueller F; Lacroix-Desmazes S
Cell Immunol; 2018 Sep; 331():22-29. PubMed ID: 29751951
[TBL] [Abstract][Full Text] [Related]
4. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
5. Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A.
Peyron I; Dimitrov JD; Delignat S; Gangadharan B; Srivastava A; Kaveri SV; Lacroix-Desmazes S
Cell Immunol; 2018 Mar; 325():64-68. PubMed ID: 29395036
[TBL] [Abstract][Full Text] [Related]
6. Biological considerations of plasma-derived and recombinant factor VIII immunogenicity.
Lai J; Hough C; Tarrant J; Lillicrap D
Blood; 2017 Jun; 129(24):3147-3154. PubMed ID: 28432221
[TBL] [Abstract][Full Text] [Related]
7. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.
Scandella DH; Nakai H; Felch M; Mondorf W; Scharrer I; Hoyer LW; Saenko EL
Thromb Res; 2001 Mar; 101(5):377-85. PubMed ID: 11297754
[TBL] [Abstract][Full Text] [Related]
8. Predictive immunogenicity of Refacto AF.
Delignat S; Repessé Y; Gilardin L; Dimitrov JD; Lone YC; Kaveri SV; Lacroix-Desmazes S
Haemophilia; 2014 Jul; 20(4):486-92. PubMed ID: 24372710
[TBL] [Abstract][Full Text] [Related]
9. Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.
Peyvandi F; Miri S; Garagiola I
Front Immunol; 2020; 11():591878. PubMed ID: 33552050
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of recombinant ovine coagulation factor VIII.
Zakas PM; Gangadharan B; Almeida-Porada G; Porada CD; Spencer HT; Doering CB
PLoS One; 2012; 7(11):e49481. PubMed ID: 23152911
[TBL] [Abstract][Full Text] [Related]
11. The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice.
Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P
Thromb Haemost; 2009 Jul; 102(1):35-41. PubMed ID: 19572065
[TBL] [Abstract][Full Text] [Related]
12. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII.
Pittman DD; Alderman EM; Tomkinson KN; Wang JH; Giles AR; Kaufman RJ
Blood; 1993 Jun; 81(11):2925-35. PubMed ID: 8499631
[TBL] [Abstract][Full Text] [Related]
13. Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A.
Gangadharan B; Delignat S; Ollivier V; Gupta N; Mackman N; Kaveri SV; Lacroix-Desmazes S
J Thromb Haemost; 2014 Dec; 12(12):2065-9. PubMed ID: 25267332
[TBL] [Abstract][Full Text] [Related]
14. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
Mannucci PM; Shi Q; Bonanad S; Klamroth R
Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
[TBL] [Abstract][Full Text] [Related]
15. Tolerating Factor VIII: Recent Progress.
Lacroix-Desmazes S; Voorberg J; Lillicrap D; Scott DW; Pratt KP
Front Immunol; 2019; 10():2991. PubMed ID: 31998296
[TBL] [Abstract][Full Text] [Related]
16. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups.
Prescott R; Nakai H; Saenko EL; Scharrer I; Nilsson IM; Humphries JE; Hurst D; Bray G; Scandella D
Blood; 1997 May; 89(10):3663-71. PubMed ID: 9160671
[TBL] [Abstract][Full Text] [Related]
17. Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.
Jankowski W; Park Y; McGill J; Maraskovsky E; Hofmann M; Diego VP; Luu BW; Howard TE; Kellerman R; Key NS; Sauna ZE
Blood Adv; 2019 May; 3(9):1429-1440. PubMed ID: 31053570
[TBL] [Abstract][Full Text] [Related]
18. Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII.
Grushin K; Miller J; Dalm D; Parker ET; Healey JF; Lollar P; Stoilova-McPhie S
Haemophilia; 2014 Sep; 20(5):723-31. PubMed ID: 24750465
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors - genetic and environmental factors.
Lillicrap D; Fijnvandraat K; Santagostino E
Haemophilia; 2014 May; 20 Suppl 4():87-93. PubMed ID: 24762282
[TBL] [Abstract][Full Text] [Related]
20. Engineering less immunogenic and antigenic FVIII proteins.
Pratt KP
Cell Immunol; 2016 Mar; 301():12-7. PubMed ID: 26566286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
